|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Peláez-García A, Barderas R, Torres S,
Hernández-Varas P, Teixidó J, Bonilla F, de Herreros AG and Casal
JI: FGFR4 role in epithelial-mesenchymal transition and its
therapeutic value in colorectal cancer. PLoS One. 8:e636952013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Turner N and Grose R: Fibroblast growth
factor signalling: From development to cancer. Nat Rev Cancer.
10:116–129. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eswarakumar VP, Lax I and Schlessinger J:
Cellular signaling by fibroblast growth factor receptors. Cytokine
Growth Factor Rev. 16:139–149. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang J, Stockton DW and Ittmann M: The
fibroblast growth factor receptor-4 Arg388 allele is associated
with prostate cancer initiation and progression. Clin Cancer Res.
10:6169–6178. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ye YW, Zhou Y, Yuan L, Wang CM, Du CY,
Zhou XY, Zheng BQ, Cao X, Sun MH, Fu H, et al: Fibroblast growth
factor receptor 4 regulates proliferation and antiapoptosis during
gastric cancer progression. Cancer. 117:5304–5313. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jiang D, Li J, Li J, Wang M, Han C, Wang
X, Zhao C and Ye Y: Combination of FGFR4 inhibitor Blu9931 and
5-fluorouracil effects on the biological characteristics of
colorectal cancer cells. Int J Oncol. 51:1611–1620. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zaid TM, Yeung TL, Thompson MS, Leung CS,
Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C,
Lopez-Berestein G, et al: Identification of FGFR4 as a potential
therapeutic target for advanced-stage, high-grade serous ovarian
cancer. Clin Cancer Res. 19:809–820. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sawey ET, Chanrion M, Cai C, Wu G, Zhang
J, Zender L, Zhao A, Busuttil RW, Yee H, Stein L, et al:
Identification of a therapeutic strategy targeting amplified FGF19
in liver cancer by Oncogenomic screening. Cancer Cell. 19:347–358.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miura S, Mitsuhashi N, Shimizu H, Kimura
F, Yoshidome H, Otsuka M, Kato A, Shida T, Okamura D and Miyazaki
M: Fibroblast growth factor 19 expression correlates with tumor
progression and poorer prognosis of hepatocellular carcinoma. BMC
Cancer. 12:562012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Punt CJ and Tol J: More is less -
combining targeted therapies in metastatic colorectal cancer. Nat
Rev Clin Oncol. 6:731–733. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Paz H, Pathak N and Yang J: Invading one
step at a time: The role of invadopodia in tumor metastasis.
Oncogene. 33:4193–4202. 2014. View Article : Google Scholar :
|
|
13
|
Pez F, Lopez A, Kim M, Wands JR, Caron de
Fromentel C and Merle P: Wnt signaling and hepatocarcinogenesis:
Molecular targets for the development of innovative anticancer
drugs. J Hepatol. 59:1107–1117. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao H, Lv F, Liang G, Huang X, Wu G,
Zhang W, Yu L, Shi L and Teng Y: FGF19 promotes
epithelial-mesenchymal transition in hepatocellular carcinoma cells
by modulating the GSK3β/ β-catenin signaling cascade via FGFR4
activation. Oncotarget. 7:13575–13586. 2016.
|
|
15
|
Zhao JH, Luo Y, Jiang YG, He DL and Wu CT:
Knockdown of β-Catenin through shRNA cause a reversal of EMT and
meta-static phenotypes induced by HIF-1α. Cancer Invest.
29:377–382. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schlessinger J: Cell signaling by receptor
tyrosine kinases. Cell. 103:211–225. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang SM, Mishina YM, Liu S, Cheung A,
Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner
S, et al: Tankyrase inhibition stabilizes axin and antagonizes Wnt
signalling. Nature. 461:614–620. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Waaler J, Machon O, Tumova L, Dinh H,
Korinek V, Wilson SR, Paulsen JE, Pedersen NM, Eide TJ, Machonova
O, et al: A novel tankyrase inhibitor decreases canonical Wnt
signaling in colon carcinoma cells and reduces tumor growth in
conditional APC mutant mice. Cancer Res. 72:2822–2832. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC cancer staging manual. 7th edition.
Springer; New York, NY: 2010
|
|
20
|
Zhang X, Ibrahimi OA, Olsen SK, Umemori H,
Mohammadi M and Ornitz DM: Receptor specificity of the fibroblast
growth factor family. The complete mammalian FGF family. J Biol
Chem. 281:15694–15700. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Haugsten EM, Wiedlocha A, Olsnes S and
Wesche J: Roles of fibroblast growth factor receptors in
carcinogenesis. Mol Cancer Res. 8:1439–1452. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shi S, Li X, You B, Shan Y, Cao X and You
Y: High Expression of FGFR4 Enhances Tumor Growth and Metastasis in
Nasopharyngeal Carcinoma. J Cancer. 6:1245–1254. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ho HK, Pok S, Streit S, Ruhe JE, Hart S,
Lim KS, Loo HL, Aung MO, Lim SG and Ullrich A: Fibroblast growth
factor receptor 4 regulates proliferation, anti-apoptosis and
alpha-fetoprotein secretion during hepatocellular carcinoma
progression and represents a potential target for therapeutic
intervention. J Hepatol. 50:118–127. 2009. View Article : Google Scholar
|
|
24
|
Streit S, Mestel DS, Schmidt M, Ullrich A
and Berking C: FGFR4 Arg388 allele correlates with tumour thickness
and FGFR4 protein expression with survival of melanoma patients. Br
J Cancer. 94:1879–1886. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Meijer D, Sieuwerts AM, Look MP, van
Agthoven T, Foekens JA and Dorssers LC: Fibroblast growth factor
receptor 4 predicts failure on tamoxifen therapy in patients with
recurrent breast cancer. Endocr Relat Cancer. 15:101–111. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li CS, Zhang SX, Liu HJ, et al: Fibroblast
growth factor receptor 4 as a potential prognostic and therapeutic
marker in colorectal cancer. Biomarkers. 19:81–85. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Conradie R, Bruggeman FJ, Ciliberto A,
Csikász-Nagy A, Novák B, Westerhoff HV and Snoep JL: Restriction
point control of the mammalian cell cycle via the cyclin E/Cdk2:p27
complex. FEBS J. 277:357–367. 2010. View Article : Google Scholar
|
|
28
|
MacDonald BT, Tamai K and He X:
Wnt/β-catenin signaling: Components, mechanisms, and diseases. Dev
Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
